NOVA MUTAÇÃO DO GENE SDHD EM PACIENTES COM PARAGANGLIOMAS DO CORPO CAROTÍDEO

PATIENTS WITH NEW SDHD GENE MUTATION WITH CAROTID BODY PARAGANGLIOMAS

Roger Rodrigues1, Maria Almeida2, João Carreiro3, Carolina Mendes1, Juliana Varino1, André Marinho1, Bárbara Pereira1, Mário Moreira1, Mafalda Botelho1, Óscar Gonçalves1, Albuquerque Matos1

1. Serviço de Angiologia e Cirurgia Vascular, Centro Hospitalar e Universitário de Coimbra
2. Centro de Neurociências e Biologia Celular, Universidade de Coimbra
3. Serviço de Cirurgia Maxilofacial, Centro Hospitalar e Universitário de Coimbra

RESUMO

Introdução: Os paragangliomas (PGLs) são neoplasias neuroendócrinas que podem ocorrer em todo o corpo onde exista paraganglia. Representando 0,03% de todos os tumores, os PGLs são extremamente raros. Embora predominantemente benignos e passíveis de cura por ressecção cirúrgica, estima-se que até 6% possam ser malignos. PGLs familiares têm um modo de transmissão autossômico dominante, e uma variabilidade fenotípica significativa. Até ao momento, foram identificados três genes associados aos PGLs familiares. Todas as subunidades de codificação (D, B e C) do complexo enzima succinato desidrogenase (SDH), fazem parte do ciclo de Krebs e da cadeia transportadora de electrões.

Objectivos: Pretende-se descrever uma nova frameshift mutation no gene SDHD identificada numa família com Paragangliomas do Corpo Carotídeo.

Resultados: A análise de mutação do probando revelou a presença de uma nova frameshift mutation, c.549delG (p.L139Ffs), no exon 4 do gene SDHD. Ambos os descendentes herdaram essa mutação patogênica, embora num deles ainda esteja subclínico.

Conclusão: Descrevemos uma nova mutação causal de frameshift na subunidade D do SDH (SDHD) numa família com Paragangliomas do Corpo Carotídeo. Esta descoberta contribui para o conhecimento do espectro mutacional do SDHD, e para ajudar o aconselhamento genético desta família. Destacamos o facto de agora ser possível oferecer a outros familiares, ainda subclínicos, um teste preditivo que permite auxiliar uma vigilância ou intervenção precoce, e consequentemente melhorar o prognóstico.

Palavras-chave
Paranganglioma; Tumor do corpo carotídeo; Paranganglioma familiar; Mutação; SDHD; Succinato desidrogenase; Cirurgia.

ABSTRACT

Paragangliomas (PGLs) are neuroendocrine neoplasms that can occur throughout the body wherever there is paraganglia. Representing 0.03% of all tumours, PGLs are extremely rare. Although predominantly benign and amenable to cure by surgical resection, up to 6% can be malignant. To date, three genes have been identified that are associated with Familial PGLs. All three encode subunits (D, B and C) of the enzyme succinate dehydrogenase complex (SDH), which is part of the Kreb's cycle and the electron transport chain. We report a novel causative frameshift mutation in the subunit D of SDH (SDHD) in a family with Carotid Body Paragangliomas. This finding contributes for extending the known mutational spectrum of SDHD, and to help the genetic counseling of this family. Noteworthy, is now possible to offer to other relatives, still sub-clinical, a predictive test that would eventually aid an early surveillance/intervention for a better prognosis.

Keywords
Carotid body paranganglioma; Familial paranganglioma; Mutation; SDHD; Succinate dehydrogenase; Surgery.

*Autor para correspondência.
Correio eletrónico: roger.cc@hotmail.com (R. Rodrigues).
INTRODUCTION

Paragangliomas (PGLs) are neuroendocrine neoplasms that can occur throughout the body wherever there is paraganglia, non-neuronal cells derived from the neural crest so named for being in close proximity to sympathetic ganglia. There are fundamentally two types of paraganglia: chromaffin or sympathetic made of chromaffin cells, which have primary endocrine functions and non-chromaffin or parasympathetic made of glomus cells, which have primary chemoreceptor functions.\(^\text{(5)}\)

Representing 0.03% of all tumors, PGLs are extremely rare. Although predominantly benign and amenable to cure by surgical resection, up to 6% can be malignant.\(^\text{(2)}\)

About 50% are found in the head and neck region, most commonly as highly vascularised carotid body tumors, which represent approximately 65% of head and neck PGLs.\(^\text{(3)}\) PGLs can also be found as aortic glomus, jugular bulb and vagal and tympanic nerves. Depending on their location, patients with carotid body PGLs may notice a slow growing and painless lateral neck mass, pulse-like sensations or voice changes.

Three different types of Carotid Body PGLs have been described in the literature: Sporadic, Familial and Hyperplastic. The Sporadic form is by far the most common type, representing approximately 85% of these tumors. The prevalence of the Familial type has varied between reported studies from as low as 5% to as high as 50%.\(^\text{(5)}\)

This wide-ranging variability stems from the existence of hidden familial cases. In the latter, diagnosis is usually made earlier (30-35 years) and there's a higher prevalence of bilateral multifocal PGLs.\(^\text{(5)}\)

The Hyperplastic form is very common in patients with chronic hypoxia, such as those in New Mexico, Peru and Colorado who live at a high altitude (>1524 meters/5000 feet above sea level) and in patients with chronic obstructive pulmonary disease (COPD) or cyanotic heart disease.\(^\text{(5)}\)

Familial PGLs have an autosomal dominant mode of inheritance, therefore all generations of a family can be affected. Nevertheless, due to their exceedingly high phenotypic variability, very different clinical manifestations can occur in patients with the same genotype, even among family members. Genetic heterogeneity, incomplete penetrance and genetic imprinting lie at the root of this phenotypic variability. To date, three genes have been identified that are associated with Familial PGLs. All three encode subunits (D, B and C) of the enzyme succinate dehydrogenase complex (SDH), which is part of the Kreb’s cycle and the electron transport chain. Defective succinate dehydrogenase has been postulated to cause an increase in the intra-cellular concentration of molecular hypoxia mediators and the vascular endothelial growth factor (VEGF), thus resulting in hyperplasia, angiogenesis, and neoplasia.\(^\text{(7)}\)

Furthermore, mutations in the SDHD gene show a parent-of-origin effect. Consequently, the disease only occurs when the mutation is inherited from the father.\(^\text{(8)}\)

To date, several different mutations in the SHDH gene have been identified, which can be consulted on “The Human Gene Mutation Database” (http://hgmd.cf.ac.uk). We report a family affected by hereditary PGL in which a novel mutation in the SDHD gene was identified.

CASE PRESENTATION

The family pedigree is presented in Figure 1.

The index case (II.1) was a 58-year-old man with a known history of bilateral PGL of the carotid body. The diagnosis had been established 35 years earlier when he first presented to the Vascular Surgery outpatient clinic for evaluation of a left latero-cervical mass. Angiography suggested a carotid body PGL that was surgically removed through subadventitial dissection. A similar mass was detected in the contralateral side 9 years later and it was also removed through subadventitial dissection. In both cases, the paraganglioma diagnosis was confirmed histologically. The current mutation analysis was conducted in the context of a systematic review of paraganglioma cases operated in the Vascular Surgery Department of Centro Hospitalar e Universitário de Coimbra (CHUC). DNA was isolated from peripheral blood using the DNA isolation kit and all the coding region of the SDHD gene (1-4 exons) was PCR amplified. The presence of the pathogenic mutation was always confirmed on a separate amplification with subse-
DISCUSSION

In the present study, the mutation analysis for SDHD gene has been performed in a family with PGLs of the carotid body. An heterozygous mutation, c.549delG; p. L139Ffs in the SDHD gene has been identified in the index case and in his two offsprings (one still unaffected). This frameshift mutation was novel, not previously described (http://hgmd.cf.ac.uk) and was located in exon 4 of the SDHD gene (Figure 3).

The analysis revealed that the patient harboured a novel frameshift mutation, c.549delG (p.L139Ffs), in exon 4 of the SDHD gene. The proband’s father (I.2) committed suicide when he was 76 years old while his mother (I.1) died of stroke. Both their DNAs were not available for testing. His sister (II.2) underwent genetic testing but the mutation was not found.

His younger son (III.2), a 23-year-old man with otherwise irrelevant past medical history, was referred to the Vascular Surgery outpatient clinic because of a painless right latero-cervical mass with progressive growth during the previous 6 months. Physical examination revealed a regular and mobile mass with approximately 6 cm of diameter, in the projection of the right carotid triangle, anterior to the sternocleidomastoid muscle and immediately above the hyoid bone. A bruit was also present. A computerized tomography angiography was ordered, suggesting a carotid body PGL compressing right carotid vessels. Selective angiography was performed 2 days before surgical removal of the tumor, and the feeding artery was successfully embolized with coils. A subadventitial tumor excision was then performed (Figure 2). The histological examination showed highly vascular tissue and clusters of Zellballen cells. The subsequent mutation analysis of SDHD exon 4 showed that he also carried the family mutation.

The proband’s eldest son (III.1, age 28 years) has also been found to carry the mutation, although at the present he remains sub-clinical. His sister, a 60-year-old woman, and her two daughters don’t display any signs or symptoms suggestive of PGL. No other case was detected in the family.
We report a family with a novel heterozygous frameshift mutation in the SDHD gene, expanding the clinical and genetic heterogeneity of hereditary PGLs. This study highlights the importance of mutation analysis for individual follow-up strategy, in particular for mutation carriers who should undergo regular clinical examination. This procedure will certainly provide an early detection of PGLs in a context of genetic counseling and thereby improve the operative outcome of these patients.

REFERENCES


